Japanese clinical trials with Takeda acellular pertussis vaccine.
Japanese clinical trials with Takeda acellular pertussis vaccine revealed that infants 3 to 8 months of age reacted sufficiently to the vaccine: anti-PT ant-FHA levels after vaccination were as high as those observed with 2 year old children. No substantial difference in general reactions was noted between infants and 2 year old children. Less local reactions were noted in infants.
Kuno-Sakai
H
H
Department of Pediatrics, School of Medicine, Totaki University, Kanagawa, Japan.
Kimura
M
M
Ozaki
K
K
Isomura
S
S
Kamiya
H
H
Nii
R
R
Kato
T
T
Horiuchi
K
K
Syukuda
Y
Y
Fujita
I
I
D000367:Age Factors; D000907:Antibodies, Bacterial / Q000096:biosynthesis; D001886:Bordetella pertussis / Q000276:immunology; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D015721:Diphtheria-Tetanus-Pertussis Vaccine / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use; D006388:Hemagglutinins / Q000276:immunology; D006801:Humans; D007115:Immunization Schedule; D007223:Infant; D007564:Japan; D010567:Pertussis Vaccine / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D010566:Virulence Factors, Bordetella / Q000276:immunology; D014917:Whooping Cough / Q000276:immunology / Q000517:prevention & control
D000907:Antibodies, Bacterial; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D006388:Hemagglutinins; D010567:Pertussis Vaccine; D010566:Virulence Factors, Bordetella